Anocca secures EUR25 million from the European Investment Bank (EIB) to support clinical development of next-generation T-cell therapies for cancer

Södertälje, Sweden, 21 December 2022 – Anocca, a fully integrated cell therapy biotechnology company, today announced that it has secured EUR 25 million Venture Debt financing from the European Investment Bank (EIB). This significant investment recognises the strength and high potential of Anocca and its transformational approach to developing T-cell therapies for cancer.

Read full release.